Group 1 - Zhongyuan Environmental Protection Co., Ltd. focuses on major strategic opportunities such as the Belt and Road Initiative and carbon neutrality goals, committing to an innovative, green, low-carbon, and high-quality development path [1][2] - The company has established a full industrial chain service capability in wastewater treatment, sludge treatment, and reclaimed water utilization, aiming for a development pattern that is rooted in Henan, covers the whole country, and extends to the world [1] - Zhongyuan Environmental actively responds to the Belt and Road Initiative by promoting advanced technologies and "one-stop" environmental service models in water treatment, solid waste disposal, and watershed management, with operations in countries like Thailand, Egypt, and the UAE [1][2] Group 2 - The company integrates digital technology with ecological protection, exploring areas such as smart water management and low-carbon parks, thereby supporting high-quality development in the ecological and environmental industry [2] - Zhongyuan Environmental emphasizes international cooperation, having engaged in technical exchanges with global partners like Veolia Environment Group, to strengthen international collaboration for a greener future [2] Group 3 - China National Nuclear Corporation's subsidiary, China Tongru, focuses on nuclear technology applications in medicine and industry, establishing a "6+N" industrial system that covers key areas such as nuclear medicine and radiation applications [3][4] - The company has developed a comprehensive solution for radioactive drugs and has built a delivery system that supplies nearly 60% of the national demand, while also maintaining a leading position in the domestic radiation source industry [3] Group 4 - China Tongru has engaged in extensive international cooperation with over 30 countries, exporting products to more than 80 nations, thereby enhancing its global presence [4] Group 5 - Yunnan Energy Investment Group leverages green energy to contribute to regional energy security and sustainable development [5][6] - The company has initiated several projects in Laos and Myanmar, including solar power and hydropower projects, significantly improving local energy supply and stability [6] Group 6 - China Copper actively responds to the Belt and Road Initiative, deepening international cooperation in resource development and supply chain security, with significant investments in Peru and Africa [8][9] - The company has established stable procurement channels with over 20 Belt and Road countries, enhancing resource security and creating numerous job opportunities [9] Group 7 - The Cuba Latin America News Agency emphasizes the importance of media cooperation in combating misinformation and promoting dialogue among nations, supporting initiatives like the Belt and Road Initiative [10][11] Group 8 - Fudan University highlights the significance of the Belt and Road Initiative in addressing regional economic governance challenges, promoting a community of shared future and regional public goods [12][13] Group 9 - Chongqing High-tech Zone has become a hub for international cooperation and technological innovation, facilitating the export of scientific achievements and enhancing trade networks [14][15] - The zone has attracted numerous semiconductor companies and developed a comprehensive service platform for enterprises looking to expand internationally [15][16]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 於其他海外監管市場發佈的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈。 茲載列原子高科股份有限公司於2025年8月28日於全國中小企業股份轉讓系統網 站(www.neeq.com.cn)刊登的「原子高科股份有限公司2025年半年度報告」，僅供 參考。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年8月28日 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行董事陳贊先生、丁建民先生及 ...

Group 1 - The core focus of recent financing activities is on embodied intelligence, robotics, and healthcare sectors, indicating strong investor interest in these areas [1][2] - The technology and manufacturing sectors remain the primary focus of the first-level market, with significant financing events reported [2] - A total of 29 financing events occurred in the domestic primary market from August 4 to August 10, with a total scale of approximately 4.12 billion RMB [1] Group 2 - The embodied intelligence and robotics sector completed 7 financing rounds, with disclosed amounts exceeding 790 million RMB, while the biopharmaceutical sector also saw 7 financing rounds totaling over 1.85 billion RMB [2] - Major financing activities were concentrated in Beijing, Guangdong, and Jiangsu provinces, with 9, 6, and 4 financing events respectively [3] Group 3 - Sequoia China and Qiming Venture Partners were notably active, each completing 2 financing rounds primarily in technology, manufacturing, and healthcare sectors [4] Group 4 - Zhejiang Xiangyinong Agricultural Development Co., Ltd. secured 25 million RMB in Series A financing, focusing on the elderly care industry [5] - Ji Tai Technology completed 400 million RMB in Series D financing, aimed at accelerating strategic initiatives including platform automation and product pipeline development [9] - The company Linggan Shike completed two rounds of financing (Pre-A and Pre-A+) with a post-investment valuation exceeding 100 million USD, focusing on intelligent creation tools for content creators [24] Group 5 - The company Yanshengchao completed several rounds of financing to support clinical development and international strategy [10] - The company Zeling Bio secured nearly 400 million RMB in B+ round financing to advance innovative drug development [13] - The company Lifebio completed several rounds of financing to enhance its research and development capabilities in biobased new materials [15]

Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on the distribution of radioactive drugs in the body to obtain physiological and pathological information [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear medicine imaging equipment, and radiation therapy devices [2] Development Environment - The Chinese government has been actively promoting the nuclear medicine industry through various policies, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - Local governments, such as in Guangdong and Sichuan, have also introduced plans to accelerate the development of the nuclear medicine sector [6][7] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant advancements in technology and capabilities, transitioning from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Nuclear Industry, East China Pharmaceutical, and Yuanda Medical, with East China Pharmaceutical holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new radioactive drug developments, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in diverse nuclear medicine services [20]

Group 1: Acquisition Overview - The company Yimai Sunshine (02522.HK) announced the acquisition of 70% equity in Guangzhou Gaomai Health Technology Co., Ltd. for a total consideration of 54 million yuan [1] - Following the acquisition, Gaomai Health will become a subsidiary of Yimai Sunshine, and its financial performance will be consolidated into Yimai Sunshine's financial statements [1] - This acquisition is expected to have a significant impact on the third-party medical imaging service industry and the overall healthcare market landscape [1] Group 2: Policy and Market Opportunities - The "One County, One Nuclear Medicine Department" policy aims to enhance the development of nuclear medicine in China, addressing long-standing issues such as insufficient supply of medical isotopes and lack of specialized talent [2] - The National Health Commission has set goals for comprehensive coverage of nuclear medicine departments in hospitals by 2025 and aims for self-supply of major medical isotopes by 2027 [2] - These policies provide strong support and development opportunities for related enterprises in the nuclear medicine sector [2] Group 3: Strategic Significance of the Acquisition - Gaomai Health specializes in nuclear medicine imaging technology and operational management services, which will enhance Yimai Sunshine's capabilities in nuclear medicine project development and management [4] - The acquisition allows Yimai Sunshine to accelerate the establishment of nuclear medicine projects in county-level areas, filling service gaps and improving grassroots healthcare levels [4] - The collaboration is expected to lead to innovative investment and operational models for hospital nuclear medicine projects [4] Group 4: Synergies and Innovations - The partnership will leverage both companies' strengths in radioactive drug development and medical imaging, promoting the application of new radioactive drugs in PET/CT services [5] - This collaboration aims to enhance diagnostic capabilities and provide reliable solutions for early screening and treatment of major diseases [5] - The companies will work together to promote third-party medical imaging services and expand their market presence both domestically and internationally [6] Group 5: Market Dynamics and Competition - The acquisition is seen as a "carrier-level" consolidation in the third-party medical imaging field, increasing market concentration and competitive pressure on smaller firms [7] - The competition will intensify in traditional medical imaging services, with key factors being service quality, pricing, and coverage [7] - Companies will need to innovate business models and enhance their overall strength to navigate the increasingly diverse competitive landscape [7] Group 6: Collaborative Innovation Trends - The acquisition is expected to drive a trend of collaborative innovation within the industry, as companies seek to enhance their competitive edge through partnerships [8] - There will be an increased focus on cooperation with research institutions to accelerate the development of new radioactive drugs [8] - The trend towards "Internet + medical imaging services" will further improve patient experience and service efficiency [8]

Core Viewpoint - Guangdong Province has issued an action plan to accelerate the high-quality development of the nuclear medicine industry from 2025 to 2030, focusing on innovation and collaboration in the sector [1]. Group 1: Development Goals - By 2030, Guangdong aims to significantly enhance its independent innovation capabilities in the nuclear medicine industry, break through key technologies, and establish several innovation platforms [1]. - The plan includes ensuring stable supply of commonly used medical isotopes and advancing a number of radiopharmaceuticals and high-end nuclear medical equipment to clinical trial stages [1]. - The goal is to achieve full coverage of nuclear medicine departments in tertiary general hospitals and cultivate 3-5 leading nuclear medicine enterprises with national influence, along with a number of specialized and innovative companies [1]. Group 2: Collaboration and Innovation - The plan encourages establishing cooperative mechanisms with major medical isotope-producing countries and promotes joint research in radiopharmaceutical development with international research institutions [1]. - There is a strong emphasis on supporting the innovation and research of radiopharmaceuticals, encouraging investments from enterprises, healthcare institutions, universities, and research institutes [1]. Group 3: Talent Development - The plan supports the optimization of academic programs in key universities such as Sun Yat-sen University and Jinan University to develop nuclear medicine specialties, including radiology, nuclear medicine, radiochemistry, and radiation protection [2].

金十数据6月16日讯，广东省发改委印发《广东省加快推动核医疗产业高质量发展行动方案（2025-2030 年）》提出，支持企业、医疗卫生机构、高校、科研院所加强新靶点、新机制、新类型放射性药物的研 发投入。加大放射性核素偶联药物研发力度，支持开展具有精准靶向性的抗体类、多肽类、小分子类放 射性创新药物研发，推动高特异性诊断标记药物、放射性治疗药物、放射性诊疗一体化药物生产与应 用。针对国外已上市、临床应用成熟的放射性药物重大品种，加快国产化替代和商业化供应。积极引进 国内外核医疗企业在我省布局放射性药物研发中心、中试平台和生产基地。 （广东省发展改革委） 广东：支持放射性药物创新研发 ...

Core Viewpoint - Beijing Xiantong International Pharmaceutical Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CICC and CITIC Securities as joint sponsors [1] Financial Performance - The company reported a net loss attributable to the parent of RMB 297 million in 2023 and RMB 149 million in 2024 [2][5] - Revenue for 2023 was RMB 10.23 million, increasing to RMB 44.064 million in 2024 [5][7] - The company incurred significant research and development expenses exceeding RMB 296 million in 2023 and RMB 228 million in 2024 [6][7] Market Focus - The company is focused on developing and commercializing radioactive drugs, aiming to become the first listed company in China with innovative or best-in-class products in this field [3] - The product pipeline includes 15 assets, with four core products: XTR008, XTR006, XTR004, and XTR003, targeting oncology, neurodegenerative diseases, and cardiovascular diseases [3] Market Growth - The global radioactive drug market is projected to grow from USD 5 billion in 2018 to USD 9.7 billion by 2024, with a compound annual growth rate (CAGR) of 11.7% [5] - In China, the market is expected to increase from RMB 3.6 billion in 2018 to RMB 7.4 billion by 2024, with a CAGR of 13.0% [5] Customer Concentration - The company has a high customer concentration, with revenue from the top five customers accounting for 95.7% in 2023 and 93.3% in 2024 [7] Shareholder Structure - The largest shareholder group holds approximately 27.03% of the voting rights as of May 23, 2025 [8] Fundraising Purpose - The funds raised will be used for the research and registration of core products, development of other candidate products, and enhancement of sales and marketing capabilities [9]

Group 1: Hand Return Group - Hand Return Group plans to list on the Hong Kong Stock Exchange on May 30, 2025, with the stock code "2621" [3] - The IPO will issue a total of 24,358,400 shares, with a subscription rate of 990 times for the Hong Kong public offering and 1.13 times for the international offering [3] - The company aims to provide insurance service solutions through its online platform, with three main platforms: Xiao Yusan, Kachaba, and Niu Bao 100 [3] - Hand Return Group is the second-largest online insurance intermediary in China, holding a 7.3% market share in long-term life insurance premiums as of 2023 [4] - The company has distributed over 1,900 products since its establishment, including more than 280 customized products [4] - Financial data shows revenues of 806 million, 1.634 billion, and 1.387 billion CNY from 2022 to 2024, with adjusted net profits of 75 million, 253 million, and 242 million CNY respectively [5] Group 2: Yingshi Innovation - Yingshi Innovation plans to open subscriptions on May 30, 2025, and is expected to list on the Sci-Tech Innovation Board in mid-June [7] - The company will issue 41 million new shares, with 20% allocated for strategic placement [7] - Yingshi Innovation specializes in smart imaging devices, focusing on panoramic and action cameras, with a global market share of 67.2% in panoramic cameras as of 2023 [8] Group 3: Lin Qingxuan - Lin Qingxuan submitted its prospectus to the Hong Kong Stock Exchange on May 29, 2025, aiming for a main board listing [10] - The brand ranks first among domestic high-end skincare brands in China by retail sales as of 2024 [11] - Financial data indicates revenues of 691 million, 805 million, and 1.21 billion CNY from 2022 to 2024, with a compound annual growth rate of 32.5% [11] Group 4: Yushi Technology - Yushi Technology submitted its prospectus on May 28, 2025, planning to list on the Hong Kong Stock Exchange [14] - The company is the largest supplier of L4-level autonomous driving solutions for airport and factory scenarios in Greater China as of 2024 [15] - Financial data shows revenues of 66 million, 161 million, and 266 million CNY from 2022 to 2024, with a compound annual growth rate of 101.3% [15] Group 5: Yisiwei Computing - Yisiwei Computing submitted its prospectus on May 30, 2025, aiming for a main board listing [19] - The company is a leading provider of RISC-V solutions in China, with over 100 system-level solutions commercialized as of 2024 [20] - Financial data indicates revenues of 2 billion, 1.752 billion, and 2.025 billion CNY from 2022 to 2024 [20] Group 6: Xian Gong Intelligent - Xian Gong Intelligent submitted its prospectus on May 27, 2025, planning to list on the Hong Kong Stock Exchange [22] - The company ranks first in global robot controller sales for two consecutive years, with a market share of 23.6% in 2024 [22] - Financial data shows revenues of 184 million, 249 million, and 339 million CNY from 2022 to 2024, with a compound annual growth rate of 35.7% [23] Group 7: Tuopu CNC - Tuopu CNC submitted its prospectus on May 26, 2025, aiming for a main board listing [27] - The company is the top supplier of five-axis CNC machine tools in China's aerospace market, with an 11.6% market share as of 2024 [29] - Financial data indicates revenues of 136 million, 335 million, and 531 million CNY from 2022 to 2024, with a compound annual growth rate of 97.9% [29] Group 8: Xiantong Pharmaceutical - Xiantong Pharmaceutical submitted its prospectus on May 26, 2025, planning to list on the Hong Kong Stock Exchange [32] - The company is the first in China to obtain approval for innovative radioactive drugs, focusing on oncology and neurodegenerative diseases [32] Group 9: Ledong Robotics - Ledong Robotics submitted its prospectus on May 30, 2025, aiming for a main board listing [35] - The company has a customer retention rate of approximately 90% in 2024, with a compound annual growth rate of about 41.4% in revenues from 2022 to 2024 [36] Group 10: Saintong Special Medical - Saintong Special Medical submitted its prospectus on May 30, 2025, planning to list on the Hong Kong Stock Exchange [38] - The company ranks first among domestic special medical food brands in China, with a market share of 6.3% as of 2024 [39] - Financial data shows revenues of 491 million, 654 million, and 834 million CNY from 2022 to 2024, with a compound annual growth rate of 30.3% [39] Group 11: Jushuitan - Jushuitan updated its prospectus on May 22, 2025, continuing its listing process on the Hong Kong Stock Exchange [41] - The company is the largest e-commerce SaaS ERP provider in China, holding a 24.4% market share as of 2024 [42] - Financial data indicates revenues of 523 million, 697 million, and 910 million CNY from 2022 to 2024, with a compound annual growth rate of 31.9% [42]

为放射性药物提供从非临床到临床转化的一体化服务。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 据IPO早知道消息，今年11月，放射性药物领域创新型企业通瑞生物制药（成都）有限公司（下 称"通瑞生物"）宣布完成超1亿美元A+轮融资。本轮融资由深创投制造业转型升级新材料基金（下 称"深创投集团"）、泰珑投资共同领投，高瓴创投（GL Ventures）、三生制药（1530.HK）、光 华梧桐、某知名产业投资机构等多家机构和产业方共同参与投资，凯乘资本担任独家财务顾问。 本轮融资将帮助进一步完善公司靶向前体发现等核心技术平台，升级创新RDC药物高通量筛选能 力，加速多条国际领先研发管线、特别是α核素RDC药物的临床开发进程，为全球患者带来更有效的 治疗方案。 随着现代医学对精准诊断和治疗的需求不断增加，放射性药物凭借其独特的优势，在肿瘤、心血管疾 病、神经系统疾病等多个领域展现出巨大的应用前景。2023年，诺华的两款放射性配体疗法药物成 功上市并在商业上取得很大成就，与此同时，礼来以14亿美元对核药企业Point实施收购，而BMS （百时美施贵宝）斥资41亿美元收购核药企业RayzeBi ...